Head-to-head evidence
ABBV-RGX-314 vs MW02
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
ABBV-RGX-314
Developed by AbbVie
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04704921 (registry estimate)
MW02
Developed by Mabwell (Shanghai) Bioscience Co., Ltd.
NCT05297292 · Phase 2/3 · status unknown
This is a randomized, quadruple-blind, active-controlled Phase 2/3 trial with a clinically meaningful primary endpoint (change in visual acuity), but no results have been posted yet, so the treatment effect versus the active comparator is still unknown.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABBV-RGX-314's landscape · MW02's landscape